Title:  Water-soluble fractions of Phlebodium decumanum and its use as nutritional supplement in AIDS and cancer patients

United States Patent:  6,228,366

Assignee:  Helsint, S.A.L. (Granada, ES)

Filed:  March 29, 1999

PCT NO:  PCT/ES98/00220

102(e) Date:  March 29, 1999

PCT PUB. Date:  February 11, 1999

A purified and standardized water-soluble fraction, prepared from the leaves of a variety of Phlebodium decumanum and identified as EXPLY-37, is adequate for the manufacturing of formulations, useful as nutritional supplements of general application, and more particularly, in patients suffering from general weakness and cachexia, such as AIDS an cancer patients. The formulations can contain, optionally, powdered Phlebodium decumanum rhizome and/or Phlebodium decumanum rhizome extract, together with the appropriate excipients for preparing said formulation as powders, capsules and syrups.

DESCRIPTION OF THE INVENTION

This invention is addressed, but not limited, to the manufacturing of a water-soluble fraction from the leaves of a cultivated variety of Phlebodium decumanum, purified and standardized, identified as EXPLY-37, to the preparation of EXPLY-37 formulations and to the use of these formulations as nutritional supplements in AIDS and cancer patients. The formulations can be used together with anti-retroviral drugs in AIDS patients and associated to conventional oncology treatments (surgery and/or radio-and chemotherapy), in order to improve the efficacy and reduce the side effects in the recovery of patients under those treatments.

1. Phlebodium decumanum

This Polypodiacee, belonging to the Subgenus Phlebodium, within the Genus Polypodium, is organically cultivated and processed in the facility near the Yojoa lake (Northern Honduras). This facility is owned by HELSINT S.A.L. (Spain) and exploited by Helechos International, Honduras, S.A. (HIH). The plant has been considered for years as Polypodium leucotomos but has been reclassified in 1992, according to the in situ studies carried out by Prof.Cirile Nelson, Director of the Herbario TEFH, Department of Biology, UNAH (Tegucigalpa, Honduras), Prof. Sinn Sandberg, Uppsala University, and Prof. Antonio Molina, from the Paul C. Stanley Herbario and the Escuela Agricola Panamericana. A full agreement has been reached on the new nomenclature. The relationships among the different Polypodium species have been furthermore reviewed by M. Vasange, Ph. Thesis, Uppsala University, 1996.

The lake Yojoa cultures are the only ones existing in the world where both ferns--Phlebodium decumanum and Polipodium leucotomos--, are cultivated.

2. Water-soluble Fractions of Phlebodium decumanum

EXPLY-37 is the tradename, property of HELSINT S.A.L. and applied to the Extract of Phlebodium decumanum from the Yojoa Lake. No 37 corresponds to the extraction method selected among those tested for the preparation of the extract from the leaves and is based on the methods disclosed in patents G B 2,024. 622 A, GB 2075,834-A, ES 8902092 and more recently in WO 96/5139.

Sporulated leaves from Phlebodium decumanum, dried and ground, are delipidated by treatment with petroleum ether, methylene choride or mixtures petroleum ether/methylene chloride, then extracted with a mixture of methanol/water. An alternative method consists in the extraction with a mixture of methyl alcohol/water followed by delipidation of the extract with petroleum ether, methylene chloride or mixtures petroleum ether/methylene chloride.

By removing the methyl alcohol at reduced pressure the remaining water-soluble fraction is purified by passing it through a mixed ion-exchange column, treatment with active charcoal, sodium metabisulphyte and filtration.

The purified water-soluble fraction is concentrated until a batch-to-batch constant and reproducible composition within a narrow range. Example 1 describes a method for the preparation of a water-soluble fraction from the leaves of Phlebodium decumanum identified as EXPLY-37. A typical composition of EXPLY-37 is shown in Table 1.

The tradename EXPLY-37 has been applied by HELSINT S:A:L to distinguish the extract from the variety of Phlebodium decumanum cultivated in the lake Yojoa facility and to differentiate it from wild varieties of Phlebodium decumanum from other origins.

A water-soluble fraction, purified and standardized, can also be obtained from the rhizome by the following method: the rhizome, after removing all the villosities, is washed with an sterilizing solution and deionized water, dried, ground, and extracted with a mixture of methyl alcohol/water. After removal of the alcohol in the vacuum, the cloudy water-soluble fraction is treated with petroleum ether, methylene chloride or mixtures petroleum ether/methylene chloride to remove the remain lipids. The solution is clarified with active charcoal, treated with sodium metabisulphite, filtered and concentrated until a batch-to-batch constant and reproducible composition, within a narrow range. Example 2 describes a method for the preparation of a water-soluble fraction, or extract, from the rhizome of Phlebodium decumanum. A typical composition of such fraction is shown on TABLE 2.

3. Formulations Containing EXPLY-37 for Use by Oral Route

The invention provides formulations containing EXPLY-37 useful as nutritional supplements. These formulations may additionally contain rhizome and/or rhizome water-soluble fraction. The formulations, adequate for oral administration, can be solid or liquid and used as powders, soft or hard gelatine capsules or syrups.

3.1 Solid Formulations Containing EXPLY-37

3.1.a) Mixture Containing Powdered Rhizome of Phlebodiun decumanum and EXPLY-37

This preparation can be obtained by a method consisting of the following steps:

successive washings of the rhizome with water containing active chlorine, de-ionized water, ethyl alcohol and de-ionized water.

drying of the rhizome

grinding of the rhizome and homegenization to a selected particle size

incorporation of EXPLY-37

drying.

This mixture of EXPLY-37 and Phlebodium decumanum rhizome, ground and homogenized, can be used as a powder to fill hard gelatine capsules containing between 100 and 500 mg powder. The ratio [ground and homogenized rhizome: EXPLY-37] in the mixture is within the range 4:1 to 1.1.

3.1.b) Mixture Containing Powdered Phlebodium decumanum Rhizomes EXPLY-37 and Phlebodium decumanum Rhizome Extract

This preparation can be obtained by a similar method to that summarised in 3.1.a), although different mixtures of EXPLY-37 and rhizome extract (50:50 to 95:5) can be added in different proportions. The solid mixture containing EXPLY-37, rhizome powder and rhizome extract of Phlebodium decumanum, prepared as a dry powder, can be used to fill hard gelatine capsules containing 100-500 mg solid powder. The relative proportions [EXPLY-37+rhizome extract]:[rhizome] can be in the range 4:1 to 1:1

3.2 Liquid Formulations Containing EXPLY-37

These formulations can be prepared as soft gelatine capsules and syrups.

3.2.a) Soft gelatine capsules containing EXPLY-37

The capsules con be filled by direct injection of diluted EXPLY-37 having the adequate viscosity. These capsules can contain 50-700 mg EXPLY-37.

3.2.b) Soft gelatine capsules containing EXPLY-37 and Phlebodium decumanum rhizome extract.

These capsules can be obtained by the following process:

Preparation of a homogeneous mixture containing EXPLY-37 and rhizome extract, the relative proportions ranging within the range (50:50 to 95:5)

Dilution of the mixture and injection in soft gelatine capsules. Total content [EXPLY-37+rhizome extract]: 50 to 750 mg.

3.2.c) Syrups containing EXPLY-37

A syrup can be prepared by homogenizing EXPLY-37 with the following components:

Saccharum officinarum liquid extract

Glycyrrhiza glabra liquid extract

Citric acid

Preferred formulations are those containing EXPLY-37 at a concentration of 50-500 mg/g.

3.2.d) Syrups containing mixtures of EXPLY-37+Phlebodium decumanum rhizome extract [relative proportions (50:50) to (95:1)] and the following components:

Sacharum officinarum liquid extract

Glycirrhiza glabra liquid extract

Citric acid

Preferred formulations are those containing the mixture [EXPLY-37+rhizome extract] at a concentration of 50-500 mg/g.

3.2.e) Syrups containing EXPLY-37.

A different syrup can be prepared by the incorporation of EXPLY-37 to an aqueous solution containing the following excipients:

invert sugar

sorbitol

propylenglycol

Preferred formulations are those containing EXPLY-37 at a concentration of 20-500 mg/ml.

3.2.f) Syrups containing EXPLY-37 and Phlebodium decumanum rhizome extract.

Syrups can be prepared by incorporating a mixture containing various proportions [EXPLY-37: rhizome extract (50:50) to (95:5)] into an aqueous solution of following excipients:

invert sugar

sorbitol

propylenglycol

Preferred formulations are those containing 20-50 mg [EXPLY-37+rhizome extract/ml]

EXPLY-37 formulations provided in this invention are useful as nutritional supplement of general use.

These formulations are, particularly adequate for the treatment of malnutrition, body weight loss, generalized wasting and cachectic syndrome in AIDS patients [see the results obtained with AIDS patients: Clinical Results. I. AIDS patients with advanced HIV infection] and as a supplement to treatments with anti-retroviral drugs. The formulations are also useful for the treatment of cancer patients showing generalized weakness and cachectic impairment: as cachexia is slowing-down and reverting, a general improvement is obtained allowing a more efficacious application of the appropriate anti-cancer treatments. EXPLY-37 formulations can also be used as adjuvant in conventional oncology treatments (surgery and/or radio- and chemotherapy) and for the recovery of cancer patients, previously under such treatments [see the results obtained in cancer patients: Clinical Results. II. Treatment of cancer patients].

Treatment of cachectic syndrome in patients with advanced HIV infection is better performed by administration of the formulations provided in this invention at daily doses comprised between 1 and 5 g, expressed as EXPLY-37. Similar doses are adequate for the treatment of cachectic syndrome in cancer patients, as adjuvant in conventional anti-cancer treatments and in the recovery of cancer patients following to those treatments.

Claim 1 of 18 Claims

What is claimed is:

1. A purified and standardized water-soluble extract obtained from the leaves of Phlebodium decumanum, said extract being commonly known as EXPLY-37, having the following characteristics:

TBL % by weight Total solid content 79.5-81.5 Ash 10-12 Total N 0.7-0.9 Total Protein 4.9-5.9 Lipids <0.2 Carbohydrates 60.5-64.5 pH 5-5.1 Refractive index 1.4-1.5 UV absorption 235-237 nm 274-284 nm Absorbance at 290 nm 2.5-5

____________________________________________
If you want to learn more about this patent, please go directly to the U.S. Patent and Trademark Office Web site to access the full patent.